Prediction of prostate cancer in extended-field biopsies of the prostate

BJU International

Volumn 93, Issue 4, 2004, Pages 516-521

  Winkler, M H ^a,d   Kulinskaya, E ^b   Gillatt, D A ^c  

^a LISTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

^d NONE   (United Kingdom)

Author keywords

Biopsy; Prediction; Prostate cancer; PSA; TRUS

Indexed keywords

BIOCHEMICAL MARKER; PROSTATE SPECIFIC ANTIGEN; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ANAMNESIS; ARTICLE; CANCER DIAGNOSIS; CLINICAL PROTOCOL; CYST; DIAGNOSTIC ACCURACY; DIGITAL RADIOGRAPHY; FAMILY HISTORY; HEALTH CARE COST; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VOLUME; URETHRA DISEASE; CONTROLLED STUDY;

AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; URINARY RETENTION;

EID: 1642288288     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04670.x     Document Type: Article

References (26)

1. Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States. Patterns of change in the era of prostate-specific antigen. World J Urol 1997; 15: 331-5
2. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61
3. Arcangeli CG, Ornstein DK, Keetch DW, Andriole GL. Prostate-specific antigen as a screening test for prostate cancer. The United States experience. Urol Clin North Am 1997; 24: 299-306
4. Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology 2001; 57: 1105-11
5. Potter SR, Horniger W, Tinzl M, Bartsch G, Partin AW. Age, prostate-specific antigen and digital rectal examination as determinants of the probability of having prostate cancer. Urology 2001; 57: 1100-4
6. Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostate-specific antigen (PSA) and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 1998; 52: 455-61
7. Catalona WJ, Southwick PC, Slawin KM et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255-60
8. Virtanen A, Gomari M, Kranse R, Stenman UH. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 1999; 45: 987-94
9. Horninger W, Volgger H, Rogatsch H et al. Consideration of low PSA cut-off levels to optimize the detection of curable prostate cancer. Eur J Cancer 2000; 36: 1322-35
10. Krumholtz JS, Carvalhal GF, Ramos CG et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60: 469-73
11. Stamey TA, Yemoto CE. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone. J Urol 2000; 163: 119-26
12. Babaian RJ, Johnston DA, Naccarato W et al. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001; 165: 757-60
13. Babaian RJ. Extended field prostate biopsy enhances cancer detection. Urology 2000; 55: 453-6
14. Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies, results of a prospective clinical trial. J Urol 2000; 163: 163-6
15. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-202
16. Flanigan RC, Catalona WJ, Richie JP et al. Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol 1994; 152: 1506-9
17. Trinkler FB, Schmid DM, Hauri D, Pei P, Maly FE, Sulser T. Free/total prostate-specific antigen ratio can prevent unnecessary prostate biopsies. Urology 1998; 52: 479-86
18. Djavan B, Remzi M, Zlotta AR et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002; 60 (Suppl. 1): 4-9
19. Fink KG, Hutarew G, Esterbauer B et al. Evaluation of transition zone and lateral sextant biopsies for prostate cancer detection after initial sextant biopsy. Urology 2003; 61: 748-53
20. Saika T, Tsushima T, Nasu Y et al. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. Cancer 2002; 94: 1685-91
21. Okihara K, Cheli CD, Partin AW et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 2002; 167: 2017-23
22. Brawer MK, Cheli CD, Neaman IE et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163: 1476-80
23. Horninger W, Cheli CD, Babaian RJ et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2-4 nanograms per milliliter. Urology 2002; 60 (Suppl. 1): 31-5
24. Naya Y, Stamey TA, Cheli CD et al. Can Volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? Urology 2002; 60 (Suppl. 1): 36-41
25. Partin AW, Brawer MK, Subong EN et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1998; 1: 197-203
26. Zhu L, Leinonen J, Zhang WM, Finne P, Stenman UH. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1- antichymotrypsin complex together with free or total PSA. Clin Chem 2003; 49: 97-103